Johnson & Johnson's Dual Energy Thermocool Smarttouch SF Platform Receives FDA Approval

Johnson & Johnson (JNJ) said Wednesday that the US Food and Drug Administration has approved its Dual Energy Thermocool Smarttouch SF Platform. The company said the platform is an integrated catheter ablation product that is intended to allow electrophysiologists to provide radiofrequency and pulsed field energy through a single catheter. It said the platform includes advanced mapping, imaging, and pulsed field Index guidance. Following approval by the US Food and Drug Administration, Johnson & Johnson said the first procedures with the platform are expected to begin in the US this summer.